Voisin Consulting Life Sciences case_study icon
Case study

A Proactive and Reactive Team in Orphan Drug Development

Post thumbnail A Proactive and Reactive Team in Orphan Drug Development

Are you in need of a proactive and reactive team in orphan drug development? An orphan drug is a designation existing in both the FDA and the EMA regulatory frameworks. It has been created in order to facilitate access to medical support for those patients suffering from rare disease.

In this case study, we highlight the specific challenges of a biopharmaceutical company commercializing their drug candidate through the European framework for orphan drug indication. Our clinical research team worked proactively and reactively in orphan drug development, by providing tailored site management and study coordination for a phase II study operated in multiple sites… Find out more by downloading below!

Voisin Consulting Life Sciences download icon

Download the full Case study now

Fill in the form to download the content

    Yes, I would like to receive communications regarding VCLS services and events

    Our Expertise

    The VCLS team has in-depth expertise enabling us to provide a highly tailored service for the most innovative healthcare products, including orphan drugs.

    Orphan Drugs